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The prognosis of patients who present with oesophageal cancer is
poor and the majority of patients die within 1 year of diagnosis
(Roth et al, 1994; O’Reilly and Forastiere, 1995). Many patients
present with locally advanced or metastatic disease, but even those
who present with apparently localized disease can often not be
cured despite aggressive local treatment. Furthermore, there has
been a dramatic increase in the incidence of oesophageal adeno-
carcinomas (Daly et al, 1996).
Multimodality treatment plays an increasingly important role
in patients with oesophageal cancer. Herskovic et al (1992)
compared radiation therapy plus chemotherapy with radiation
therapy alone. Median survival was prolonged and late relapses
were fewer in the patients who received combined therapy. We
have conducted a trial comparing surgery plus neoadjuvant
chemotherapy with the combination of cisplatin and etoposide
followed by surgery in patients with resectable squamous cell
carcinoma of the oesophagus, and found that preoperative
chemotherapy significantly improved survival (Kok et al, 1997).
On the contrary, in the intergroup trial, in which patients with
squamous cell carcinomas and adenocarcinomas of the oesoph-
agus were randomized between preoperative chemotherapy with
cisplatin and 5-fluorouracil (5-Fu) followed by surgery versus
surgery alone, no survival difference was observed between both
groups (Kelsen et al, 1997).
The treatment for patients with locally advanced, or metastatic,
disease is still unsatisfactory. Many phase II trials have been
performed in which most chemotherapy regimens consisted of a
combination of cisplatin with another agent such as 5-Fu or etopo-
side (Kok et al, 1996; Kok, 1997). Response rates in the order of
15–40% are usually reported, but the effect on survival remains
undetermined.
Paclitaxel has substantial activity in a variety of malignancies,
especially ovarian and breast cancer (Holmes et al, 1990; McGuire
et al, 1990). At a dose of paclitaxel of 250 mg m–2, by 24-h infu-
sion every 3 weeks, a response rate of 32% was reported in 50
evaluable patients with carcinoma of the oesophagus (Ajani et al,
1994). Paclitaxel administered over 3 h in combination with
cisplatin and 5-Fu yielded an overall response rate of 45% (Ajani
et al, 1996).
Since we are looking for a more active chemotherapy combina-
tion than previously used (Kok et al, 1997), which also can be
administered as neoadjuvant chemotherapy in the shortest possible
period before surgery, we performed a dose-finding study with a
fixed dose of cisplatin and escalating doses of paclitaxel given
every 2 weeks.
PATIENTS AND METHODS
This dose-finding study was initiated to determine the toxicities
and maximum tolerated dose (MTD) of a combination of pacli-
taxel and cisplatin given every 2 weeks in patients with metastatic
or local-regional unresectable adenocarcinoma, undifferentiated or
squamous cell carcinoma of the esophagus or oesophageal–gastric
junction area. Eligibility requirements were a life expectancy of 12
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weeks or greater; age ³ 18; ECOG performance status 0, 1, or
2; written and voluntary informed consent; adequate haemato-
logical; renal and hepatic functions as defined by: granulocytes
³ 1.5 ´ 109 l–1, platelets ³ 100 ´ 109 l–1, total bilirubin ≤ 1.5 ´ upper
normal limit and creatinine ≤ 120 mmol l–1.
The starting dose of paclitaxel was 100 mg m–2 and cisplatin
60 mg m–2 given by intravenous (i.v.) infusion every 2 weeks. At
subsequent levels, the dose of paclitaxel was increased by
10 mg m–2. After prehydration with at least one litre of normal
saline, the total calculated dose of paclitaxel, diluted in 500 ml of
normal saline, was infused over 3 h. Hereafter the calculated dose
of cisplatin was administered over 3 h, followed by post-hydration
over 24 h. All patients were premedicated with dexamethasone
20 mg given orally 12 and 6 h prior to the paclitaxel infusion.
Thirty minutes before the paclitaxel infusion, the patients received
10 mg dexamethasone, 2 mg clemastine and 50 mg ranitidine, all
given i.v. Ondansetron was given as anti-emetic prophylaxis.
Patients were retreated when the granulocytes were > 0.75 ´ 109 l–1
and the platelets > 75 ´ 109 l–1.
Response and toxicity determined the duration of treatment.
Patients with stable disease received up to a maximum of six
cycles of treatment. In patients achieving a partial or complete
response, an additional two cycles were allowed. Treatment was
discontinued in patients with disease progression. Toxicity was
graded and reported using CTC criteria and response was evalu-
ated using standard WHO criteria. Patients were evaluated for
response after the third and sixth course and after discontinuation
of therapy. In general, response evaluation was performed by a
computerized tomography scan of the chest and upper abdomen,
and ultrasonography of the supraclavicular and/or celiac lymph-
nodes whenever appropriate. Patients with the primary tumour in
situ were also evaluated by endoscopy.
Haematological dose-limiting toxicity was defined as CTC
grade III or IV neutropenia with infection or fever requiring
parenteral antibiotics, or CTC grade III or IV thromocytopenia
requiring two or more platelet transfusions within one cycle, or
resulting in ³ CTC grade 2 haemorrhage. Non-haematological
dose-limiting toxicity was defined as CTC grade III or IV non-
haematological toxic effects, with the exception of nausea and
emesis. Dose reduction/treatment delay dose-limiting toxicity was
defined as dose reductions and/or treatment delay for ³ 1 week for
reasons of toxicity. The MTD was reached if ³ two of three
patients had treatment delay dose-limiting toxicity during the first
two cycles at a given dose level. If dose-limiting toxicity of any
type was seen in one of three patients within the first two cycles at
a given level, three more patients were enrolled at this dose level.
If ³ two of six patients experienced dose-limiting toxicity, that
dose level was considered the maximum tolerated dose. Patient
characteristics are listed in Table 1.
RESULTS
Fifty-eight of the 64 patients entered into this study received at
least three cycles of treatment. The reasons for fewer treatment
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Figure 1 Dose levels of paclitaxel versus dose intensity1054 A van der Gaast et al
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cycles were the following: one patient died of upper gastro-
intestinal bleeding without thrombocytopenia 8 days after the start
of chemotherapy; one patient’s condition deteriorated after the first
course of chemotherapy because of an aspiration pneumonia, and
further treatment was withheld; one patient developed signs of
spinal cord compression due to bone metastases a few days after
start of chemotherapy, was treated with radiotherapy and went off
study; one patient died of ruptured aortic aneurysm 21 days after
start of chemotherapy; one patient had disease progression after
one cycle; and one patient developed a cholestatic hepatitis after
two cycles, most probably due to a combination of amoxicillin and
clavulanic acid. This treatment had been prescribed because of
respiratory infection before start of chemotherapy.
The paclitaxel dose was escalated from 100 mg m–2 to
200 mg m–2 and a total of 362 cycles of treatment were adminis-
tered with a median number of six cycles (range 1–8).
Haematological dose-limiting toxicity was not reached. Sixty-nine
per cent of the patients received at least six cycles of treatment.
Sixty-one chemotherapy cycles were delayed in 33 (57%) of the
58 patients who received at least three cycles of chemotherapy.
Forty-five cycles in 24 patients were delayed for a maximum of
1 week because of a granulocyte count < 0.75 ´ 109 l–1. The details
of the treatment delays are shown in Table 2. A dose reduction was
applied in one patient at the dose level 200 mg m–2 of paclitaxel
because of granulocytopenic fever in the preceding course. The
achieved dose intensity of paclitaxel in milligrams per square
metre per week (mg m–2 per week), calculated over six cycles per
dose level, is shown in Figure 1.
The frequency of grade 3 and 4 leucocytopenia and granulo-
cytopenia only slightly increased at the higher dose levels. Three
patients experienced granulocytopenic fever. The first patient
mentioned earlier, who was treaded with radiotherapy after the
start of chemotherapy, was admitted with granulocytopenic fever
14 days after start of chemotherapy. The other two patients were
treated at dose level of 200 mg m–2 paclitaxel and had granulo-
cytopenic fever after the first and third cycles respectively. All
three patients recovered. Grade 1 thrombocytopenia was observed
in five patients at paclitaxel dose levels of 140 mg m–2 (one
patient), 150 mg m–2 (one patient), 180 mg m–2 (one patient) and
200 mg m–2 (two patients). Two patients had grade 2 thrombocy-
topenia at the dose levels of 130 and 140 mg m–2 of paclitaxel. No
grade 3 or 4 thrombocytopenia was observed at any dose level.
The worst haematological toxicity per dose levels for all patients
who received at least three cycles of treatment is listed in Table 3.
The neurotoxicity per dose level is presented in Table 4. A clear
increase in the neurotoxicity can be observed at the higher dose
levels. Almost all these patients had a neuro-sensory toxicity char-
acterized by paraesthesiae and sensory loss sometimes interfering
with functioning. Frequently, the onset or worsening of the neuro-
toxicity occurred after treatment had been stopped and was only
partially reversible. At the dose level of 200 mg m–2 of paclitaxel
in five patients’ treatment was discontinued after the fourth or fifth
cycle because of grade 2 or 3 neuroxtoxicity.
Table 1 Patients’ characteristics
Characteristic No. of patients (%)
Total patients 64
Sex
Female 17 (27)
Male 47 (73)
Age, years
Median 56
Range 37–74
Performance status (Karnofsky)
60% 2 (3)
70% 8 (12)
80% 12 (19)
90% 32 (50)
100% 9 (14)
Unknown 1 (2)
Histology
Adenocarcinoma 33 (52)
Squamous cell carcinoma 30 (47)
Undifferentiated carcinoma 1 (1)
Extent of disease
Locally advanced/unresectable 13 (20)
Primary with distant metastases 41 (64)
Metastases after prior resection 10 (16)
Metastatic sites
Supraclavicular lymph nodes 16 (25)
Celiac lymph nodes 26 (41)
Liver 7 (11)
Bone 2 (3)
Mediastinal recurrence 4 (6)
Other 15 (23)
Table 2 Treatment delays due to granulocytopenia during the first six cycles in patients who received at least three cycles of chemotherapy
Paclitaxel dose No. of No. of patients No. of courses Total no.
(mg m–2) patients with a delay with a delay of courses
(% delayed)
100 3 0 0 18 (0%)
110 3 1 2 18 (11%)
120 3 0 0 17 (0%)
130 3 2 3 18 (17%)
140 6 4 8 36 (22%)
150 7 3 6 35 (17%)
160 6 3 5 36 (14%)
170 6 2 3 33 (9%)
180 6 2 5 35 (14%)
190 5 2 5 30 (17%)
200 10 5 8 45 (18%)Biweekly treatment with cisplatin and paclitaxel in oesophageal cancer 1055
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The other toxicities were usually mild and easily manageable,
and not substantially worse at the higher dose levels. A summary
of these toxicities is listed in Table 5. Two patients had grade 3
nephrotoxicity after the sixth and eighth cycle. The first patient
was admitted 2 weeks after the sixth cycle because of an obstruc-
tive uropathy complicated by a urosepsis without leucocytopenia
or granulocytopenia. Despite intensive treatment, the patient died.
The second patient had a reversible impairment of the renal func-
tion after the eighth cycle, which was most probably due to the use
of a non-steroidal anti-inflammatory agent.
Fifty-nine patients were evaluable for response. Two patients (3%)
had a complete response with a duration of 5 and 7 months. Twenty-
nine patients (49%) achieved a partial response with a median dura-
tion of 7 months (range 3–16+ months). Eighteen patients (31%) had
stable disease with a median duration of 5 months (range 3–11+
months) and ten patients (17%) progressed. Seventeen of the 29
patients (59%) with an adenocarcinoma had a partial response, and
14 of the 29 patients (48%) with a squamous cell carcinoma, had a
partial or complete response. Responses were observed at all dose
levels and there was no indication for a dose–response relationship.
Table 3 Worst grade of leucocytopenia per dose level
Grade
Paclitaxel dose No. of patients 0 1 2 3 4
(mg m–2)
Leucocytes (granulocytes)
100 3 1 (0) 1 (1) 1 (0) 0 (1) 0 (1)
110 3 0 (0) 1 (1) 2 (0) 0 (1) 0 (1)
120 3 1 (0) 0 (1) 2 (0) 0 (2) 0 (0)
130 3 0 (0) 1 (0) 2 (0) 0 (1) 0 (2)
140 6 0 (0) 1 (0) 3 (0) 2 (3) 0 (3)
150 7 1 (0) 0 (1) 4 (1) 2 (1) 0 (4)
160 6 1 (0) 1 (1) 3 (3) 2 (1) 0 (2)
170 6 1 (0) 1 (2) 3 (1) 1 (2) 0 (1)
180 6 0 (0) 2 (1) 2 (1) 2 (3) 0 (1)
190 5 1 (1) 2 (1) 2 (0) 0 (2) 0 (1)
200 10 2 (1) 1 (0) 4 (2) 2 (1) 1 (6)
Table 4 Worst grade neurotoxicity per dose level
Paclitaxel dose
Grade
(mg m–2) No. of patients 0 1 2 3 4
100 3 2 0 1 0 0
110 3 3 0 0 0 0
120 3 2 1 0 0 0
130 3 2 1 0 0 0
140 6 4 2 0 0 0
150 7 3 2 1 1 0
160 6 1 4 1 0 0
170 6 4 1 1 0 0
180 6 2 4 0 0 0
190 5 1 1 1 2 0
200 10 0 1 4 5 0
Table 5 Worst grade other toxicities (CTC) at all dose levels (minimum number of courses = 3)
Grade
No. of patients 0 1 2 3 4
Haemoglobin 58 9 25 22 2
Alopecia 58 2 1 55
Nausea 58 11 23 21 3
Vomiting 58 26 14 10 8
Mucositis 58 51 7
Nephrotoxicity 58 55 1 2
Myalgia 58 20 25 13
Fatigue 58 21 22 14 11056 A van der Gaast et al
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DISCUSSION
Paclitaxel either given as a single agent or in combination with
cisplatin is usually administered once every 3 weeks. However,
since the period of neutropenia is usually brief, shorter inter-treat-
ment intervals may be possible to increase dose density. Studies
with weekly or biweekly paclitaxel have been reported (Parimoo
et al, 1996; Fennelly et al, 1997).
In two phase I studies, a fixed dose of cisplatin of 60 mg m–2 and
an escalating dose of paclitaxel by 3-h infusion in a biweekly
schedule was tested (Gelmon et al, 1996a; Swenerton et al, 1996).
In the study of Swenerton et al (1996) granulocytopenia, which
prevented retreatment at the scheduled time, was the dose-limiting
toxicity at a paclitaxel dose level of 120 mg m–2. Two of the six
patients had granulocytopenia (< 0.75 ´ 109 l–1) on day 14 of the
first cycle at this dose level. In the study of Gelmon et al (1996a)
dose-limiting neutropenia was seen at a paclitaxel dose of
100 mg m–2. The latter study included 27 patients with metastatic
breast cancer, most of whom had received prior adjuvant
chemotherapy. In the subsequent phase II study with paclitaxel
90 mg m–2 and cisplatin 60 mg m–2, responses were observed in
85% of the assessable patients (Gelmon et al, 1996a). In two other
phase II trials of biweekly paclitaxel by 3-hour infusion and
cisplatin in advanced breast cancer using the same dose–response,
rates of 23% and 60% were observed in 13 and 25 patients respec-
tively (McCaskill-Stevens et al, 1996; Sparano et al, 1997).
Sørensen et al (1997) reported a response rate of 43% in 40
evaluable patients with non-small-cell lung cancer using a
biweekly schedule of cisplatin 60 mg m–2 and a 3-h infusion of
paclitaxel 110 mg m–2. In a phase I/II study in patients with non-
small-cell lung cancer of biweekly paclitaxel and a fixed dose of
60 mg m–2 cisplatin, the dose of paclitaxel could be escalated to
140 mg m–2 without dose-limiting toxicity (Gelmon et al, 1996b).
Such data suggest that the dose-limiting toxicity may be dependent
on patient selection and/or tumour type, or other presently
unknown factors.
In our study, it was possible to increase the dose of paclitaxel to
200 mg m–2 in combination with 60 mg m–2 cisplatin. Haemato-
logical dose-limiting toxicity was not observed. Surprisingly the
percentage of treatment delays due to granulocytopenia did not
substantially increase with the higher dosages of paclitaxel. The dose
intensity of paclitaxel calculated over 6 cycles rose from 50 mg m–2
per week to approximately 85 mg m–2 per week. Only three episodes
of granulocytopenic fever were observed in three patients. This
suggests that retreatment is safe when the granulocyte count is
> 0.75 ´ 109 l–1.
Cumulative sensory neuropathy became the dose-limiting toxi-
city and was the reason that, at the dose level of 200 mg m–2, 50%
of the patients did not complete the planned six cycles of treat-
ment. Also, at the dose level of 190 mg m–2 two patients eventually
developed a grade 3 neuropathy. Neuropathy caused by paclitaxel
is related to the absolute dose of paclitaxel administered during
each course, and the cumulative dose (Rowinsky et al, 1993).
Although the severity of the peripheral neuropathy is correlated
with paclitaxel Css, the absolute dose administered during each
course seems to be equally predictive for the development of
neuropathy. Connelly et al (1996) suggested potentiation of pacli-
taxel’s neuropathy by cisplatin when paclitaxel was given over 3 h
rather than over 24 h. However, a disadvantage of a 24-h infusion
duration of paclitaxel instead of a 3-h infusion duration is the
occurrence of more profound myelosuppression (Eisenhauer et al,
1994). It is unclear whether a treatment interval of 2 weeks instead
of 3 weeks between courses also influences the severity of
neuropathy caused by the combination of cisplatin and paclitaxel.
Hilkens et al (1995) found no increase in neurotoxicity with more
intensive dosing schedules of cisplatin within a cumulative dose
range of 280–675 mg m–2. At the higher dose levels, we found that
the neuropathy often had a rapid onset, as has also been recently
reported in a phase I dose-escalating study with paclitaxel admin-
istered over 3 h and cisplatin administered over 4 h in a 3-weekly
schedule (Gordon et al, 1997).
Other toxicities were usually mild and the observed response
rate of 52% in 59 evaluable patients is a very promising result in
this patient group.
In conclusion, in a biweekly schedule with a fixed dose of
60 mg m–2 cisplatin, it is possible to increase the dose of paclitaxel
to 200 mg m–2 without encountering haematological dose-limiting
toxicity. At the dose levels 190 mg m–2 and 200 mg m–2 of pacli-
taxel, grade 3 neurotoxicity was frequently seen and was the
reason that, at the last dose level, 50% of the patients had to stop
treatment prematurely. Consequently, 180 mg m–2 paclitaxel in
combination with 60 mg m–2 cisplatin seems to be the maximum
tolerable dose. The observed response rate in this study certainly
warrants further investigation of this biweekly schedule in patients
with oesophageal cancer.
ACKNOWLEDGEMENT
This study was supported by a grant from Bristol-Meyers-Squibb.
REFERENCES
Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM and Kelsen DP (1994)
Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma
of the esophagus. J Natl Cancer Inst 86: 1086–1091
Ajani JA, Ilson DH and Kelsen DP (1996) Paclitaxel in the treatment of patients
with upper gastrointestinal carcinomas. Semin Oncol 23: 55–58
Connelly E, Markman M, Kennedy A, Webster K, Kulp B, Peterson G and Belinson
J (1996) Paclitaxel delivered as 3-hr infusion with cisplatin in patients with
gynecologic cancers: unexpected incidence of neurotoxicity. Gynecol Oncol 62:
166–168
Daly JM, Karnell L and Menck HR (1996) National Cancer Data Base report on
esophageal carcinoma. Cancer 78: 1820–1828
Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van
der Burg MEL, Kerr I, Vermorken JB, Buser K, Colombo N, Bacon M,
Santabarbara P, Onetto N, Winograd W and Canetta R (1994) European-
Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose
versus low-dose and long versus short infusion. J Clin Oncol 12: 2654–2666
Fennelly D, Aghajanian C, Shapiro F, O’Flaherty C, McKenzie M, O’Connor C,
Tong W, Norton L and Spriggs D (1997) Phase I and pharmacologic study of
paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin
Oncol 15: 187–192
Gelmon KA, O’Reilly SE, Tolcher AW, Campbell C, Bryce C, Ragaz J, Coppin C,
Plenderleith IH, Ayers D, McDermott B, Nakashima L, Healy D and Onetto N
(1996a) Phase I/II trial of bi-weekly paclitaxel and cisplatin in the treatment of
metastatic breast cancer. J Clin Oncol 14: 1185–1191
Gelmon KA, Murray N, Melosky B, Shah A, Page R, Dulude H and Rielly S.
(1996b) Phase I/II study of biweekly paclitaxel and cisplatin in non-small-cell
lung cancer. Proc Am Soc Clin Oncol 15: 405 (Abstract)
Gordon AN, Stringer CA, Matthews CM, Willis DL and Nemunaitis J (1997) Phase
I dose escalation of paclitaxel in patients with advanced ovarian cancer
receiving cisplatin: rapid development of neurotoxicity is dose-limiting. J Clin
Oncol 15: 1965–1973
Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper
J, Byhardt R, Davis L and Emami B (1992) Combined chemotherapy and
radiotherapy compared with radiotherapy alone in patients with cancer of the
esophagus. N Engl J Med 326: 1593–1598Biweekly treatment with cisplatin and paclitaxel in oesophageal cancer 1057
British Journal of Cancer (1999) 80(7), 1052–1057 © 1999 Cancer Research Campaign 
Hilkens PH, van der Burg ME, Moll JW, Planting AS, van Putten WL, Vecht CJ and
van den Bent MJ (1995) Neurotoxicity is not enhanced by increased dose
intensities of cisplatin administration. Eur J Cancer 31: 678–681
Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar
AU, Frye DK and Hortobagyi GN (1990) Phase II trial of Taxol, an active drug
in the treatment of metastatic breast cancer. J Natl Cancer Inst 82: 1247–1249
Kelsen D, Ginsberg R, Qian C, Gunderson L, Mortimer J, Estes N, Hailer D, Ajani J,
Kocha W, Roth J and Minsky B (1997) Chemotherapy followed by operation
versus operation alone in the treatment of patients with localized esophageal
cancer: a preliminary report of intergroup study 113 (RTOG 89-11). Proc Am
Soc Clin Oncol 16: 276 (Abstract)
Kok TC, van der Gaast A, Stoter G, Tilanus H, Eykenboom W, Dees J, van
Overhagen H and Splinter T (1996) Cisplatin and etoposide in esophageal
cancer. A phase II study. Br J Cancer 74: 980–984
Kok TC (1997) Chemotherapy in esophageal cancer: a review. Cancer Treat Rev 23:
65–85
Kok TC, van Lanschot J, Siersema PD, van Overhagen H and Tilanus HW (1997)
Neoadjuvant chemotherapy in operable esophageal squamous cell cancer: final
report of a phase III multicenter randomized controlled trial. Proc Am Soc Clin
Oncol 16: 277 (Abstract)
McCaskill-Stevens W, Ansari R, Fisher W, Pennington K, Dobbs C, Gonin R,
Schaefer S, Loesch D and Sledge G (1996) Phase II study of biweekly cisplatin
and paclitaxel in the treatment of metastatic breast cancer. Proc Am Soc Clin
Oncol 15: 120 (Abstract)
McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-
Pearson DL and Davidson M (1996) Cyclophosphamide and cisplatin
compared with paclitaxel and cisplatin in patients with stage III and IV ovarian
cancer. N Engl J Med 334: 1–6
O’Reilly S and Forastiere A (1995) Is surgery necessary with multimodality
treatment of esophageal cancer? Ann Oncol 6: 519–521
Parimoo D, Garcia A, Muggia F, Dimery I, Rogers M and Jeffers S (1996) Tolerance
of paclitaxel (Taxol) 3-hr infusion with G-CSF on a biweekly schedule. Proc
Am Soc Clin Oncol 15: 181 (Abstract)
Roth JA and Putnam JB Jr (1994) Surgery for cancer of the esophagus. Sem Oncol
21: 453–461
Rowinsky EK, Chaudhry V, Forastiere A, Sartorius SE, Ettinger DS, Grochow LB,
Lubejko BG, Cornblath DR and Donehower RC (1993) Phase I and
pharmacologic study of paclitaxel and cisplatin with granulocyte colony-
stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol 11:
2010–2020
Sørenson JB, Wedervang K and Dombernowsky P (1997) Preliminary results of a
phase II study of paclitaxel and cisplatin in patients with non-small cell lung
cancer. Semin Oncol 24: S12.18–S12.20
Sparano JA, Neuberg D, Glick JH, Robert NJ, Goldstein LJ, Sledge GW and Wood
W (1997) Phase II trial of bi-weekly paclitaxel and cisplatin in advanced breast
carcinoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 15:
1880–1004
Swenerton K, Hoskins P, Stuart G, Batist G, Pike J, Onetto N, Fisher B and
Eisenhauer E (1996) A phase I study of biweekly paclitaxel/cisplatin as initial
therapy for advanced ovarian cancer. A study of the National Cancer Institute
of Canada Clinical Trials Group. Ann Oncol 7: 1077–1079